Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Neoadjuvant Nab-paclitaxel in Triple-negative or HER2-positive Breast Cancer

NCT03907800 is registered in ClinicalTrials.gov with Ruijin Hospital as lead sponsor.

NCT NCT03907800
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03907800 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Neoadjuvant Nab-paclitaxel in Triple-negative or HER2-positive Breast Cancer
Lead sponsor
Ruijin Hospital
Phase
Phase 2
Overall status
Unknown status
Start date
April 1, 2019
Completion date
October 31, 2022
Enrollment
100 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

breast cancer, her2-positive breast cancer, triple negative breast cancer